YTHDF1 regulates immune cell infiltration in gastric cancer via interaction with p53

Liao,Quan; Xiong,Jianping

doi:10.3892/etm.2024.12543

YTHDF1 regulates immune cell infiltration in gastric cancer via interaction with p53

Authors:
- Quan Liao
- Jianping Xiong
View Affiliations

Affiliations: Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China
Published online on: April 17, 2024 https://doi.org/10.3892/etm.2024.12543
Article Number: 255
Copyright: © Liao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The N6‑methyladenosine reader YTH N6‑methyladenosine RNA binding protein 1 (YTHDF1) has been assessed in several tumor types and holds significance in the tumor microenvironment (TME). Furthermore, p53, an important tumor suppressor, is closely associated with the TME. The present study evaluated the roles of YTHDF1 and p53 in regulating the TME in gastric cancer (GC). Genetic alterations in the YTH domain family were analyzed using the cBioPortal database. Expression of YTHDF1 in GC cells and tissues was assessed using the Tumor Immune Estimation Resource (TIMER), Gene Expression Profiling Interactive Analysis (GEPIA), University of Alabama at Birmingham Cancer data analysis portal and Tumor‑Immune System Interactions and Drug Bank (TISIDB) databases, along with reverse‑transcription‑quantitative PCR and western blotting in GC. The prognostic value of multiple tumors was determined using Kaplan‑Meier analysis. Correlation analyses were performed using the TIMER, TISIDB and GEPIA databases. Protein‑protein interactions of YTHDF1 were predicted using GeneMANIA and HitPredict, and confirmed using co‑immunoprecipitation. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses of the YTHDF1 functional network in GC were performed using LinkedOmics. Genetic alterations revealed that, among the YTH domain family members, YTHDF1 had the highest alteration in GC and was associated with a shorter survival. Additionally, YTHDF1 was significantly negatively associated with the level of CD8⁺ T cells, B cells, macrophages, dendritic cells (DCs) and neutrophils in GC. Furthermore, tumor associate macrophage‑related and DC markers were significantly negatively correlated with YTHDF1 expression, whilst regulatory T cells and T cell exhaustion markers were significantly negatively associated with YTHDF1 expression. In addition, compared with that in p53‑nonmutant GC cells, YTHDF1 expression was significantly higher in p53‑mutated GC cells, indicating a potential association between YTHDF1 and p53. Analyses using the GeneMANIA and HitPredict databases, and co‑immunoprecipitation, demonstrated that YTHDF1 interacted with p53. In conclusion, the findings of the present study indicate that YTHDF1 is associated with a poor prognosis and serves an important role in the TME of GC. We hypothesize, for the first time to the best of our knowledge, that YTHDF1 regulates immune cell infiltration by interacting with p53 in GC, which provides a promising direction for future research.

View Figures

View References

1	Joshi SS and Badgwell BD: Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 71:264–279. 2021.PubMed/NCBI View Article : Google Scholar
2	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.PubMed/NCBI View Article : Google Scholar
3	Gong J, Chehrazi-Raffle A, Reddi S and Salgia R: Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: A comprehensive review of registration trials and future considerations. J Immunother Cancer. 6(8)2018.PubMed/NCBI View Article : Google Scholar
4	Desrosiers R, Friderici K and Rottman F: Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. Proc Natl Acad Sci USA. 71:3971–3975. 1974.PubMed/NCBI View Article : Google Scholar
5	Zaccara S, Ries RJ and Jaffrey SR: Reading, writing and erasing mRNA methylation. Nat Rev Mol Cell Biol. 20:608–624. 2019.PubMed/NCBI View Article : Google Scholar
6	Wang L, Hui H, Agrawal K, Kang Y, Li N, Tang R, Yuan J and Rana TM: m⁶A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy. EMBO J. 39(e104514)2020.PubMed/NCBI View Article : Google Scholar
7	Huang H, Wang Y, Kandpal M, Zhao G, Cardenas H, Ji Y, Chaparala A, Tanner EJ, Chen J, Davuluri RV and Matei D: FTO-dependent N ⁶-methyladenosine modifications inhibit ovarian cancer stem cell self-renewal by blocking cAMP signaling. Cancer Res. 80:3200–3214. 2020.PubMed/NCBI View Article : Google Scholar
8	Tang B, Yang Y, Kang M, Wang Y, Wang Y, Bi Y, He S and Shimamoto F: m⁶A demethylase ALKBH5 inhibits pancreatic cancer tumorigenesis by decreasing WIF-1 RNA methylation and mediating Wnt signaling. Mol Cancer. 19(3)2020.PubMed/NCBI View Article : Google Scholar
9	Xiao W, Adhikari S, Dahal U, Chen YS, Hao YJ, Sun BF, Sun HY, Li A, Ping XL, Lai WY, et al: Nuclear m⁶A reader YTHDC1 regulates mRNA splicing. Mol Cell. 61:507–519. 2016.PubMed/NCBI View Article : Google Scholar
10	Wojtas MN, Pandey RR, Mendel M, Homolka D, Sachidanandam R and Pillai RS: Regulation of m⁶A transcripts by the 3'→5' RNA helicase YTHDC2 is essential for a successful meiotic program in the mammalian germline. Mol Cell. 68:374–387.e12. 2017.PubMed/NCBI View Article : Google Scholar
11	Zhang C, Huang S, Zhuang H, Ruan S, Zhou Z, Huang K, Ji F, Ma Z, Hou B and He X: YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation. Oncogene. 39:4507–4518. 2020.PubMed/NCBI View Article : Google Scholar
12	Chang G, Shi L, Ye Y, Shi H, Zeng L, Tiwary S, Huse JT, Huo L, Ma L, Ma Y, et al: YTHDF3 induces the translation of m6A-enriched gene transcripts to promote breast cancer brain metastasis. Cancer Cell. 38:857–871.e7. 2020.PubMed/NCBI View Article : Google Scholar
13	Jia R, Chai P, Wang S, Sun B, Xu Y, Yang Y, Ge S, Jia R, Yang YG and Fan X: m⁶A modification suppresses ocular melanoma through modulating HINT2 mRNA translation. Mol Cancer. 18(161)2019.PubMed/NCBI View Article : Google Scholar
14	Liu T, Wei Q, Jin J, Luo Q, Liu Y, Yang Y, Cheng C, Li L, Pi J, Si Y, et al: The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation. Nucleic Acids Res. 48:3816–3831. 2020.PubMed/NCBI View Article : Google Scholar
15	Zhao X, Chen Y, Mao Q, Jiang X, Jiang W, Chen J, Xu W, Zhong L and Sun X: Overexpression of YTHDF1 is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Biomark. 21:859–868. 2018.PubMed/NCBI View Article : Google Scholar
16	Hu Y, Pan Q, Wang M, Ai X, Yan Y, Tian Y, Jing Y, Tang P and Jiang J: m⁶A RNA methylation regulator YTHDF1 correlated with immune microenvironment predicts clinical outcomes and therapeutic efficacy in breast cancer. Front Med (Lausanne). 8(667543)2021.PubMed/NCBI View Article : Google Scholar
17	Wang Q, Zhang Q, Li Q and Zhang J and Zhang J: Clinicopathological and immunological characterization of RNA m⁶A methylation regulators in ovarian cancer. Mol Genet Genomic Med. 9(e1547)2021.PubMed/NCBI View Article : Google Scholar
18	Li T, Gu M, Deng A and Qian C: Increased expression of YTHDF1 and HNRNPA2B1 as potent biomarkers for melanoma: A systematic analysis. Cancer Cell Int. 20(239)2020.PubMed/NCBI View Article : Google Scholar
19	Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 6(pl1)2013.PubMed/NCBI View Article : Google Scholar
20	Huang KK, Ramnarayanan K, Zhu F, Srivastava S, Xu C, Tan ALK, Lee M, Tay S, Das K, Xing M, et al: Genomic and epigenomic profiling of high-risk intestinal metaplasia reveals molecular determinants of progression to gastric cancer. Cancer Cell. 33:137–150.e5. 2018.PubMed/NCBI View Article : Google Scholar
21	Wang K, Yuen ST, Xu J, Lee SP, Yan HH, Shi ST, Siu HC, Deng S, Chu KM, Law S, et al: Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet. 46:573–582. 2014.PubMed/NCBI View Article : Google Scholar
22	Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 513:202–209. 2014.PubMed/NCBI View Article : Google Scholar
23	Kakiuchi M, Nishizawa T, Ueda H, Gotoh K, Tanaka A, Hayashi A, Yamamoto S, Tatsuno K, Katoh H, Watanabe Y, et al: Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. Nat Genet. 46:583–587. 2014.PubMed/NCBI View Article : Google Scholar
24	Wang K, Kan J, Yuen ST, Shi ST, Chu KM, Law S, Chan TL, Kan Z, Chan AS, Tsui WY, et al: Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet. 43:1219–1223. 2011.PubMed/NCBI View Article : Google Scholar
25	Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B and Liu XS: TIMER: A web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 77:e108–e110. 2017.PubMed/NCBI View Article : Google Scholar
26	Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and Varambally S: UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 19:649–658. 2017.PubMed/NCBI View Article : Google Scholar
27	Ru B, Wong CN, Tong Y, Zhong JY, Zhong SSW, Wu WC, Chu KC, Wong CY, Lau CY, Chen I, et al: TISIDB: An integrated repository portal for tumor-immune system interactions. Bioinformatics. 35:4200–4202. 2019.PubMed/NCBI View Article : Google Scholar
28	Lánczky A and Győrffy B: Web-based survival analysis tool tailored for medical research (KMplot): Development and implementation. J Med Internet Res. 23(e27633)2021.PubMed/NCBI View Article : Google Scholar
29	Tang Z, Li C, Kang B, Gao G, Li C and Zhang Z: GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102. 2017.PubMed/NCBI View Article : Google Scholar
30	Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, Franz M, Grouios C, Kazi F, Lopes CT, et al: The GeneMANIA prediction server: Biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 38:W214–W220. 2010.PubMed/NCBI View Article : Google Scholar
31	Patil A, Nakai K and Nakamura H: HitPredict: A database of quality assessed protein-protein interactions in nine species. Nucleic Acids Res. 39:D744–D749. 2011.PubMed/NCBI View Article : Google Scholar
32	Vasaikar SV, Straub P, Wang J and Zhang B: LinkedOmics: Analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 46:D956–D963. 2018.PubMed/NCBI View Article : Google Scholar
33	Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S and Madden TL: Primer-BLAST: A tool to design target-specific primers for polymerase chain reaction. BMC Bioinformatics. 13(134)2012.PubMed/NCBI View Article : Google Scholar
34	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
35	Li K, Zhang A, Li X, Zhang H and Zhao L: Advances in clinical immunotherapy for gastric cancer. Biochim Biophys Acta Rev Cancer. 1876(188615)2021.PubMed/NCBI View Article : Google Scholar
36	Zhang C, Liu J, Xu D, Zhang T, Hu W and Feng Z: Gain-of-function mutant p53 in cancer progression and therapy. J Mol Cell Biol. 12:674–687. 2020.PubMed/NCBI View Article : Google Scholar
37	Hanahan D: Hallmarks of cancer: New dimensions. Cancer Discov. 12:31–46. 2022.PubMed/NCBI View Article : Google Scholar
38	Pitt JM, Marabelle A, Eggermont A, Soria JC, Kroemer G and Zitvogel L: Targeting the tumor microenvironment: Removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. 72:1482–1492. 2016.PubMed/NCBI View Article : Google Scholar
39	Cui Y and Guo G: Immunomodulatory function of the tumor suppressor p53 in host immune response and the tumor microenvironment. Int J Mol Sci. 17(1942)2016.PubMed/NCBI View Article : Google Scholar
40	Qi F, Li J, Qi Z, Zhang J, Zhou B, Yang B, Qin W, Cui W and Xia J: Comprehensive metabolic profiling and genome-wide analysis reveal therapeutic modalities for hepatocellular carcinoma. Research (Wash D C). 6(0036)2023.PubMed/NCBI View Article : Google Scholar
41	Zetrini AE, Lip H, Abbasi AZ, Alradwan I, Ahmed T, He C, Henderson JT, Ranth AM and Wu X: Remodeling tumor immune microenvironment by using polymer-lipid-manganese dioxide nanoparticles with radiation therapy to boost immune response of castration-resistant prostate cancer. Research (Wash D C). 6(0247)2023.PubMed/NCBI View Article : Google Scholar
42	Duan X, Du H, Yuan M, Liu L, Liu R and Shi J: Bioinformatics analysis of necroptosis-related lncRNAs and immune infiltration, and prediction of the prognosis of patients with esophageal carcinoma. Exp Ther Med. 26(331)2023.PubMed/NCBI View Article : Google Scholar
43	Chen H, Yu Y, Yang M, Huang H, Ma S, Hu J, Xi Z, Guo H, Yao G, Yang L, et al: YTHDF1 promotes breast cancer progression by facilitating FOXM1 translation in an m6A-dependent manner. Cell Biosci. 12(19)2022.PubMed/NCBI View Article : Google Scholar
44	Pi J, Wang W, Ji M, Wang X, Wei X, Jin J, Liu T, Qiang J, Qi Z, Li F, et al: YTHDF1 Promotes Gastric Carcinogenesis by Controlling Translation of FZD7. Cancer Res. 81:2651–2665. 2021.PubMed/NCBI View Article : Google Scholar
45	Chen XY, Liang R, Yi YC, Fan HN, Chen M, Zhang J and Zhu JS: The m⁶A reader YTHDF1 facilitates the tumorigenesis and metastasis of gastric cancer via USP14 translation in an m⁶A-dependent manner. Front Cell Dev Biol. 9(647702)2021.PubMed/NCBI View Article : Google Scholar
46	Liu XS, Kui XY, Gao Y, Chen XQ, Zeng J, Liu XY, Zhang Y, Zhang YH and Pei ZJ: Comprehensive analysis of YTHDF1 immune infiltrates and ceRNA in human esophageal carcinoma. Front Genet. 13(835265)2022.PubMed/NCBI View Article : Google Scholar
47	Tsuchiya K, Yoshimura K, Inoue Y, Iwashita Y, Yamada H, Kawase A, Watanabe T, Tanahashi M, Ogawa H, Funai K, et al: YTHDF1 and YTHDF2 are associated with better patient survival and an inflamed tumor-immune microenvironment in non-small-cell lung cancer. OncoImmunology. 10(1962656)2021.PubMed/NCBI View Article : Google Scholar
48	Han D, Liu J, Chen C, Dong L, Liu Y, Chang R, Huang X, Liu Y, Wang J, Dougherty U, et al: Anti-tumour immunity controlled through mRNA m⁶A methylation and YTHDF1 in dendritic cells. Nature. 566:270–274. 2019.PubMed/NCBI View Article : Google Scholar
49	Bai X, Wong CC, Pan Y, Chen H, Liu W, Zhai J, Kang W, Shi Y, Yamamoto M, Tsukamoto T, et al: Loss of YTHDF1 in gastric tumors restores sensitivity to antitumor immunity by recruiting mature dendritic cells. J Immunother Cancer. 10(e003663)2022.PubMed/NCBI View Article : Google Scholar
50	Shevach EM: Fatal attraction: Tumors beckon regulatory T cells. Nat Med. 10:900–901. 2004.PubMed/NCBI View Article : Google Scholar
51	Petersen RP, Campa MJ, Sperlazza J, Conlon D, Joshi MB, Harpole DH Jr and Patz EF Jr: Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer. 107:2866–2872. 2006.PubMed/NCBI View Article : Google Scholar
52	Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL and Banham AH: Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 24:5373–5380. 2006.PubMed/NCBI View Article : Google Scholar
53	Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, Xu Y, Li YW and Tang ZY: Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 25:2586–2593. 2007.PubMed/NCBI View Article : Google Scholar
54	Perrone G, Ruffini PA, Catalano V, Spino C, Santini D, Muretto P, Spoto C, Zingaretti C, Sisti V, Alessandroni P, et al: Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur J Cancer. 44:1875–1882. 2008.PubMed/NCBI View Article : Google Scholar
55	Georgiev P, Charbonnier LM and Chatila TA: Regulatory T cells: The many faces of Foxp3. J Clin Immunol. 39:623–640. 2019.PubMed/NCBI View Article : Google Scholar
56	Terranova-Barberio M, Pawlowska N, Dhawan M, Moasser M, Chien AJ, Melisko ME, Rugo H, Rahimi R, Deal T, Daud A, et al: Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer. Nat Commun. 11(3584)2020.PubMed/NCBI View Article : Google Scholar
57	Jin K, Cao Y, Gu Y, Fang H, Fei Y, Wang J, Liu X, Lv K, He X, Lin C, et al: Poor clinical outcomes and immunoevasive contexture in CXCL13+CD8+ T cells enriched gastric cancer patients. Oncoimmunology. 10(1915560)2021.PubMed/NCBI View Article : Google Scholar
58	Zarour HM: Reversing T-cell dysfunction and exhaustion in cancer. Clin Cancer Res. 22:1856–1864. 2016.PubMed/NCBI View Article : Google Scholar
59	Zhao T, Sun D, Zhao M, Lai Y, Liu Y and Zhang Z: N⁶-methyladenosine mediates arsenite-induced human keratinocyte transformation by suppressing p53 activation. Environ Pollut. 259(113908)2020.PubMed/NCBI View Article : Google Scholar
60	Kwok CT, Marshall AD, Rasko JE and Wong JJ: Genetic alterations of m⁶A regulators predict poorer survival in acute myeloid leukemia. J Hematol Oncol. 10(39)2017.PubMed/NCBI View Article : Google Scholar
61	Xu A, Liu M, Huang MF, Zhang Y, Hu R, Gingold JA, Liu Y, Zhu D, Chien CS, Wang WC, et al: Rewired m⁶A epitranscriptomic networks link mutant p53 to neoplastic transformation. Nat Commun. 14(1694)2023.PubMed/NCBI View Article : Google Scholar
62	Hassin O and Oren M: Drugging p53 in cancer: One protein, many targets. Nat Rev Drug Discov. 22:127–144. 2023.PubMed/NCBI View Article : Google Scholar
63	Zeng Y and Jin RU: Molecular pathogenesis, targeted therapies, and future perspectives for gastric cancer. Semin Cancer Biol. 86:566–582. 2022.PubMed/NCBI View Article : Google Scholar